A Phase 3 interventional study of AXS-05 (dextromethorphan-bupropion) and Bupropion in Smoking Cessation, sponsored by Axsome Therapeutics, Inc.. Recruiting at 28 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.
Among the 48 studies testing bupropion in Smoking Cessation, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 14 in phase 3, and was the 48th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of Kansas Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 17
First in 1998; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 705 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 162 across the 48 interventional studies. Of the 42 that completed or were terminated, 22 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 48 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
1 of the studies testing bupropion in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies testing bupropion in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trial to evaluate the efficacy and safety of AXS-05 compared to placebo and bupropion for smoking cessation in adults.
Eligible subjects will be randomized in a 1:1:1 ratio to receive AXS-05, bupropion, or placebo for 12 weeks, followed by an 18-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Up to 12 weeks
Drug: AXS-05 (dextromethorphan-bupropion)
Up to 12 weeks
Drug: Bupropion
Up to 12 weeks
Drug: Placebo
AXS-05 tablets, taken twice daily for 12 weeks.
Bupropion tablets, taken twice daily for 12 weeks.
Placebo tablets, taken twice daily for 12 weeks.
4-Week Continuous Smoking Abstinence Rate
Time frame: Weeks 9 to 12
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dextromethorphan/Bupropion Tablet AXS-05 · Bupropion